To the best of our knowledge, the SKM-1 cell line, which was established in the leukaemic phase during the progression from MDS to AML, is karyotypically abnormal (including a 17p deletion) and is characteristic of the acquisition of p53 mutations (missense and silent point mutations)30, 31. The gene discussed is TP53; the disease is myelodysplastic syndrome.